LAB: Amendment: SEC Form S-4/A filed by Standard BioTools Inc.
Stocks in this Quantisnow insightIndustrials
Full content unavailable. See the original source below.
Historical context for LAB
Across the 15 sessions after earlier LAB headlines, the stock closed higher 6 times and lower 9 times, with a median move of 3.1% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | LAB | SPY |
|---|---|---|---|
| Oct 6, 2026 | Standard BioTools Announces Agreement to Sell Microfluidics Business to ARCHIMED | -5.4% | +0.5% |
| Oct 1, 2026 | Standard BioTools Provides Update on Sale of Mass Cytometry Business | -1.7% | +0.2% |
| Aug 6, 2026 | Standard BioTools Reports Second Quarter 2026 Financial Results | +2.0% | -0.2% |
| Jul 28, 2026 | Standard BioTools Announces Sale of Mass Cytometry Business and Illumina’s Buyout of Contingent Payments to Advance Merger with Treeline Biosciences | +2.6% | +0.2% |
| Jul 22, 2026 | Standard BioTools to Announce Second Quarter 2026 Financial Results on August 5, 2026 | -7.4% | -0.1% |
| Jul 20, 2026 | Standard BioTools Announces Filing of Registration Statement in Connection with Treeline Biosciences Transaction | -5.0% | -0.2% |
Quantisnow market dataNASDAQ
LAB
Standard BioTools Inc.
- Market cap
- 30-day
- Sector
- Industrials
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Listed since
- 2011
Get push alerts for LAB
Full LAB profile on Quantisnow Follow LAB and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time